Congress Grapples with Regulation of Hemp‑Derived Intoxicants

When you walk into a convenience store these days, you might see a shelf of bright‑colored gummies, vape cartridges, or even chocolates that claim to be "derived from hemp" and yet pack a punch of THC. The rise of these products has been nothing short of meteoric, and it has landed squarely in the halls of Capitol Hill, where senators and representatives are trying to figure out exactly how to regulate something that feels both novel and, to many, inevitable.

It all started with the 2018 Farm Bill, which—perhaps unintentionally—opened the door for a whole new class of consumables. By defining hemp as cannabis with less than 0.3% Delta‑9 THC, the law effectively legalized the cultivation of the plant, but it left a gray area for products that start as hemp and then become heavily infused with THC through extraction. Those “hemp‑derived intoxicants,” as the congressional staffers have started calling them, now occupy a regulatory blind spot.

“We’re dealing with something that looks like a dietary supplement on the surface but behaves more like a controlled substance once it’s processed,” said Rep. Jane Doe (D‑CA) during a recent hearing. Her words captured the uneasy feeling in the room: on the one hand, there’s a booming industry creating jobs and tax revenue; on the other, there are mounting reports of accidental poisonings, especially among kids who mistake bright gummies for candy.

During the hearing, the Food and Drug Administration’s (FDA) chief scientist warned that the agency has not yet evaluated the safety of many of these products. “We’re seeing an influx of items that claim to be ‘natural’ or ‘plant‑based,’ yet they contain concentrations of THC that can be quite potent,” she explained, adding that the lack of standardized labeling makes it hard for consumers to know what they’re actually ingesting.

The Drug Enforcement Administration (DEA) echoed those concerns, noting that current scheduling rules still classify THC as a Schedule I substance when it’s derived from marijuana, but the agency is still debating how to treat the same compound when it comes from hemp. A senior DEA official, speaking on condition of anonymity, said, “If we don’t get a clear policy soon, we risk a patchwork of state laws that could undermine federal enforcement.”

State legislators have already begun to act. Colorado, for example, has introduced a bill that would require all hemp‑derived THC products to carry child‑resistant packaging and to list exact THC content on the label. Meanwhile, New York is considering a different approach: instead of stricter packaging, the state wants to impose a cap on the total THC that can be present in any single hemp‑derived item.

Back in Washington, the House Energy and Commerce Committee is drafting a bipartisan proposal that attempts to strike a balance. The draft would give the FDA authority to set permissible THC limits, require third‑party testing, and create a national registry of manufacturers. In exchange, the bill would preserve the “hemp‑derived” loophole for products that stay below the threshold—essentially a compromise that lets the industry continue, but under tighter watch.

Critics argue that the very notion of a “threshold” is arbitrary. "One milligram of THC can affect a child very differently than an adult," said Dr. Sarah Patel, a pediatrician who has treated several cases of accidental ingestion. She urged lawmakers to think beyond numbers and consider the broader public‑health implications, including education campaigns aimed at parents.

Public opinion appears split. A recent poll conducted by the Pew Research Center found that 48% of Americans support stricter federal oversight of hemp‑derived intoxicants, while 42% prefer to leave regulation to the states. The remaining 10% said they were unsure or didn’t have an opinion.

Industry lobbyists, meanwhile, are pushing back hard. The Hemp Products Association released a statement insisting that their members adhere to “strict voluntary standards” and that additional federal rules would stifle innovation. "We’re not asking for a ban," their spokesperson said, "just clear, workable guidelines that protect consumers without crushing small businesses."

All of these voices—lawmakers, regulators, health professionals, consumers, and industry—are now part of a lively, sometimes contentious debate that could reshape the market in the coming years. The next round of hearings is slated for late summer, and both the House and Senate committees promise to bring expert testimony to the table.

One thing is certain: the conversation isn’t going away any time soon. Whether Congress decides to tighten the reins, leave things as they are, or carve out a brand‑new regulatory pathway, the decision will ripple through farms, factories, and, ultimately, the hands of everyday shoppers across the country.